Clinical Investigator Financial Interest Inquiries May Be Costly For Industry
Executive Summary
Clinical trial sponsors face "prohibitive" costs in developing internal mechanisms to verify clinical investigators' financial interests in the sponsor company, R.W. Johnson's Janice Little said at the Drug Information Association's annual meeting in Baltimore June 29.
You may also be interested in...
Financial Disclosure Reports May Be Required For Pharmacodynamic Studies
Pharmacodynamic studies may be included in "covered" studies for the purposes of FDA's financial disclosure guidance if the study is critical to an application filing.
Financial Disclosure Reports May Be Required For Pharmacodynamic Studies
Pharmacodynamic studies may be included in "covered" studies for the purposes of FDA's financial disclosure guidance if the study is critical to an application filing.
Investigator/Firm Financial Ties May Trigger Heavier Scrutiny Of Data By FDA
Disclosure of financial arrangements between a clinical investigator and study sponsor will lead to a more stringent product review at FDA, Office of Drug Evaluation I Associate Director-Regulatory Affairs Linda Carter told the Food & Drug Law Institute.